Please login to the form below

Not currently logged in
Email:
Password:

Iris Pauporté joins OSE Immunotherapeutics

She becomes clinical project director at the French biotech

OSE Immunotherapeutics Iris PauportéNantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director.

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential in other cancer indications.

She brings over 20 years of biomedical and clinical research experience to the team, and joins from the French National Cancer Institute (INCa) where she supervised the insitute's breast cancer research programme.

Prior to this, Pauporté worked for the UNICANCER hospital group as a project leader overseeing both clinical research and regulatory affairs. She also brings experience as a research coordinator at Takeda Laboratories, where she served between 1997 and 2004.

Alain Chatelin, medical director at OSE Immunotherapeutics, said: “We are very pleased to have Iris join our team.

“She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology.”

28th September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics